TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ullevål PersonalityProject. A Randomized Controlled Trial of Intensive Daytreatment Followed by Outpatient Long-term Combined Treatment Compared With Eclectic Individual Therapy for Patients With Personality Disorders
Brief Summary: Ullevål PersonalityProject is a ranomized controlled trial of treatment of patients with personality disorder. It's main purpose is to test the effect of a long-term combined treatment program compared with eclectic individual therapy for patients with personality disorders.

The main study hypothesis is that long-term combined treatment is superior to eclectic individual therapy with respect to improvement in personality functioning, psychosocial functioning, symptoms, interpersonal problems, and self destructive behavior for poorly functioning patients with personality disorders.


Options:
A: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): Dialectical Behavior Therapy
B: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy
C: Arm Label: dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy | Arm Label: treatment as usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT | Arm Label: Receiving no treatment at all; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy; Assigned to Arm(s): dialectical behavior therapy | Intervention Type: OTHER; Name: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT; Assigned to Arm(s): treatment as usual
D: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ullevål PersonalityProject. A Randomized Controlled Trial of Intensive Daytreatment Followed by Outpatient Long-term Combined Treatment Compared With Eclectic Individual Therapy for Patients With Personality Disorders
Brief Summary: Ullevål PersonalityProject is a ranomized controlled trial of treatment of patients with personality disorder. It's main purpose is to test the effect of a long-term combined treatment program compared with eclectic individual therapy for patients with personality disorders.

The main study hypothesis is that long-term combined treatment is superior to eclectic individual therapy with respect to improvement in personality functioning, psychosocial functioning, symptoms, interpersonal problems, and self destructive behavior for poorly functioning patients with personality disorders.


Options:
A: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2
D: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ullevål PersonalityProject. A Randomized Controlled Trial of Intensive Daytreatment Followed by Outpatient Long-term Combined Treatment Compared With Eclectic Individual Therapy for Patients With Personality Disorders
Brief Summary: Ullevål PersonalityProject is a ranomized controlled trial of treatment of patients with personality disorder. It's main purpose is to test the effect of a long-term combined treatment program compared with eclectic individual therapy for patients with personality disorders.

The main study hypothesis is that long-term combined treatment is superior to eclectic individual therapy with respect to improvement in personality functioning, psychosocial functioning, symptoms, interpersonal problems, and self destructive behavior for poorly functioning patients with personality disorders.


Options:
A: Arm Label: PTSD-EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EMDR | Arm Label: Integrated DBT-EMDR; Type: EXPERIMENTAL; Interventions: Behavioral: EMDR, Behavioral: DBT | Intervention Type: BEHAVIORAL; Name: EMDR; Assigned to Arm(s): Integrated DBT-EMDR, PTSD-EMDR | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Integrated DBT-EMDR
B: Arm Label: I ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ziprasidone | Arm Label: II placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): I ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II placebo
C: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation
D: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions
Brief Summary: The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.


Options:
A: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
B: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.


Options:
A: Arm Label: sparsentan; Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Arm Label: irbesartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irbesartan | Arm Label: dapagliflozin + sparsentan (Sub study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan, Drug: Dapagliflozin | Arm Label: sparsentan (Sub Study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Intervention Type: DRUG; Name: sparsentan; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study), sparsentan, sparsentan (Sub Study) | Intervention Type: DRUG; Name: irbesartan; Assigned to Arm(s): irbesartan | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study)
B: Arm Label: Abelmoschus manihot (AM); Type: EXPERIMENTAL; Interventions: Drug: Abelmoschus manihot | Arm Label: Losartan; Type: EXPERIMENTAL; Interventions: Drug: Losartan | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Abelmoschus manihot; Assigned to Arm(s): Abelmoschus manihot (AM)
C: Intervention Type: DRUG; Name: prednisone + Inhibace/Cozaar; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Inhibace/Cozaar; Assigned to Arm(s): N/A
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren, Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): I, II

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.


Options:
A: Arm Label: Tacrolimus group; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: NEFECON 8 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: NEFECON 16 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: NEFECON; Assigned to Arm(s): NEFECON 16 mg/day, NEFECON 8 mg/day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: prednisone + Inhibace/Cozaar; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Inhibace/Cozaar; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.
Brief Summary: We will compare the effectiveness of Quixil and Tranexamic acid in reducing bleeding during hip and knee joint replacements.


Options:
A: Intervention Type: DRUG; Name: IV Tranexamic acid 10mg/kg pt body weight; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quixil topical sealant; Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Physiologic saline | Arm Label: TXA-250 group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid, Drug: Physiologic saline | Arm Label: TXA-500 group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid, Drug: Physiologic saline | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA-250 group, TXA-500 group | Intervention Type: DRUG; Name: Physiologic saline; Assigned to Arm(s): Control group, TXA-250 group, TXA-500 group
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9% NaCl) | Arm Label: Topical; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Arm Label: Systemic; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Systemic, Topical | Intervention Type: DRUG; Name: Normal saline (0.9% NaCl); Assigned to Arm(s): Control, Systemic, Topical
D: Arm Label: Topical tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical tranexamic acid, Drug: Enoxaparin | Arm Label: Floseal®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Floseal®, Drug: Enoxaparin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Topical tranexamic acid; Assigned to Arm(s): Topical tranexamic acid | Intervention Type: DRUG; Name: Floseal®; Assigned to Arm(s): Floseal® | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Control group, Floseal®, Topical tranexamic acid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM).
Brief Summary: Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The evidence suggests that that HSV is an important cofactor in HIV transmission.

The trial's purpose is to assess the reduction in HIV shedding associated with valacyclovir for suppression of HSV-2 reactivation.

This proof-of-concept, randomized, double-blind, placebo controlled crossover trial of 20 HIV/HSV-2 co-infected men, assessed the effects of daily valacyclovir on HIV-1 levels in the plasma and rectal mucosa secretions.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Benzathine Penicillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzathine Penicillin, Drug: Doxycycline | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Benzathine Penicillin; Assigned to Arm(s): Benzathine Penicillin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Benzathine Penicillin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acyclovir placebo | Intervention Type: DRUG; Name: Acyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Acyclovir placebo; Assigned to Arm(s): 2
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM
Brief Summary: The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields (termed TTFields).


Options:
A: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib
B: Arm Label: Surgical Group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 (pre-surgery), Drug: PD 0332991, Procedure: Resection as clinical care | Arm Label: Non-surgical group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 | Intervention Type: DRUG; Name: PD 0332991 (pre-surgery); Assigned to Arm(s): Surgical Group | Intervention Type: DRUG; Name: PD 0332991; Assigned to Arm(s): Non-surgical group, Surgical Group | Intervention Type: PROCEDURE; Name: Resection as clinical care; Assigned to Arm(s): Surgical Group
C: Arm Label: ADV-TK/GCV; Type: EXPERIMENTAL; Interventions: Biological: ADV-TK/GCV | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: systemic chemotherapy | Intervention Type: BIOLOGICAL; Name: ADV-TK/GCV; Assigned to Arm(s): ADV-TK/GCV | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Control group | Intervention Type: DRUG; Name: systemic chemotherapy; Assigned to Arm(s): Control group
D: Arm Label: Best Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Device: NovoTTF-100A | Arm Label: NovoTTF-100A; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A | Intervention Type: DEVICE; Name: NovoTTF-100A; Assigned to Arm(s): Best Standard of Care, NovoTTF-100A

Answer: D